Order results by:
| Issue | Title | |
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract similar documents |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| "... Organization recommendations. Results. Treatment of COVID-19 with tixagevimab and cilgavimab results ..." | ||
| Vol 10, No 1 (2017) | THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES | Abstract similar documents |
| N. Z. Musina, V. K. Fedyaeva | ||
| "... This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia ..." | ||
| Vol 5, No 3 (2012) | COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES | Abstract similar documents |
| M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova | ||
| "... -adjusted life years - QALY. The analysis will be performed for the health systems. Mean QALY in the first ..." | ||
| Vol 6, No 4 (2013) | Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа | Abstract similar documents |
| A. Yu. Kulikov, I. V. Novikov | ||
| "... and effectiveness in terms of QALY are compared for liraglutide, glimepiride and rosiglitazone, all in combination ..." | ||
| Vol 15, No 3 (2022) | Economic burden of the novel coronavirus infection: a systematic review | Abstract similar documents |
| V. M. Timiryanova, I. A. Lakman, N. Sh. Zagidullin, D. F. Gareeva | ||
| "... Background. The sudden emergence and rapid spread of the novel coronavirus infection (COVID-19 ..." | ||
| Vol 6, No 3 (2013) | METHODOLOGICAL BASIS OF STANDARD GAMBLE METHOD USAGE IN QUALITY OF LIFE ASSESSMENT IN PHARMACOECONOMIC RESEARCHES | Abstract similar documents |
| R. I. Yagudina, A. Ju. Kulikov, D. T. Ugrekhelidze | ||
| Vol 11, No 4 (2018) | International experience in determining the cost-effectiveness thresholds | Abstract similar documents |
| T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky | ||
| "... , which is represented by quality-adjusted life year (QALY) in most counties. However,PolandandBrazilallow ..." | ||
| Vol 12, No 3 (2019) | Availability and Pharmacoeconomics of Insulin Therapy in Countries with the Largest Number of Diabetics | Abstract PDF (Eng) similar documents |
| S. V. Ponomarenko | ||
| Vol 13, No 4 (2020) | Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system | Abstract similar documents |
| T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky | ||
| "... cost-effectiveness standard, it was 1,748,623.36 Rub for QALY; according to the method ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic aspects of COVID-19 treatment | Abstract similar documents |
| I. V. Rogova, E. A. Zhidkova, I. A. Popova, A. V. Zaborovskiy, K. G. Gurevich | ||
| "... The article provides an overview of global trends in various treatment approaches for COVID-19 ..." | ||
| Vol 13, No 2 (2020) | COVID-19 pandemic: protective role of vitamin D | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, G. Kh. Gabdulina | ||
| "... Introduction. The COVID-19 pandemic revealed the vulnerability of the general population ..." | ||
| Vol 16, No 1 (2023) | Efficiency of Levilimab in patients with moderate and severe COVID-19 | Abstract similar documents |
| Yu. M. Gomon, V. V. Strizheletsky, I. G. Ivanov, Yu. E. Balykina, M. V. Ermolyev, A. S. Kolbin, M. V. Livshits, T. A. Usmanova, A. M. Fakhrutdinova, Yu. S. Konstantinova, A. P. Gubanov | ||
| "... of moderate and severe COVID-19 based on real world data (RWD). Material and methods. A single-center ..." | ||
| Vol 15, No 4 (2022) | Dietary factors influencing the COVID-19 epidemic process | Abstract PDF (Eng) similar documents |
| S. V. Ponomarenko | ||
| "... Coronavirus and identify factors that correlate withthe reduction in the severity of the consequences of COVID ..." | ||
| Vol 14, No 2 (2021) | Impact of disease information (Ebola and COVID-19) on the pharmaceutical sector in Russia and USA | Abstract similar documents |
| E. A. Fedorova, D. O. Afanasyev, A. V. Sokolov, M. P. Lazarev | ||
| "... and methods. The empirical base of the study includes more than 700 thousand tweets on Ebola and COVID-19 ..." | ||
| Vol 13, No 4 (2020) | Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm | Abstract similar documents |
| M. Yu. Frolov, A. S. Salasyuk, V. A. Rogov | ||
| "... )-6 drugs: tocilizumab, olokizumab, and levilimab in patients with severe COVID-19 and cytokine storm ..." | ||
| Vol 6, No 2 (2013) | PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION | Abstract similar documents |
| V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina | ||
| "... (QALY) is growing, which makes it advisable to use ART in health care on larger scale. ..." | ||
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| "... prevented (DALY) and the cost of quality-adjusted life-year saved (QALY) were determined by the suppling ..." | ||
| Vol 14, No 3 (2021) | COVID-19 pandemic prediction model based on machine learning in selected regions of the Russian Federation | Abstract similar documents |
| D. V. Gavrilov, R. V. Abramov, А. V. Kirilkina, А. А. Ivshin, R. E. Novitskiy | ||
| "... Background. Prediction of the new coronavirus infection (COVID-19) spread is important to take ..." | ||
| Vol 14, No 1 (2021) | Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19 | Abstract similar documents |
| O. V. Zhukova, A. L. Khokhlov | ||
| "... Background. Severe forms of COVID-19 are associated with the development of a cytokine storm ..." | ||
| Vol 15, No 1 (2022) | A systematic review of real-world clinical practice data in COVID-19: non-interventional studies | Abstract similar documents |
| S. A. Mishinova, Yu. M. Gomon, A. S. Kolbin, V. V. Strizheletsky, I. G. Ivanov | ||
| "... . A search strategy for the terms “COVID-19 AND real-life”, “COVID-19 AND real-data”, “COVID-19 AND real ..." | ||
| Vol 9, No 1 (2016) | COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN | Abstract similar documents |
| V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva | ||
| "... , improves the quality of life of patients, adding 0.73 QALY per patient. Modelling suggests ..." | ||
| Vol 16, No 1 (2023) | Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program | Abstract similar documents |
| T. O. Bessonova, P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov, N. Z. Musina | ||
| "... years, and the model cycle was 1 year. The outcomes used were quality-adjusted life years (QALY), life ..." | ||
| Vol 14, No 2 (2021) | Chemoreactome screening of pharmaceutical effects on SARS-CoV-2 and human virome to help decide on drug-based COVID-19 therapy | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, A. G. Chuchalin, Yu. I. Zhuravlev | ||
| "... and safe drug-based treatment for COVID-19. Another approach seems promising: to reprofile ..." | ||
| Vol 15, No 2 (2022) | Clinical study of real-time polymerase chain reaction test kit for SARS-CoV-2 ribonucleic acids detection | Abstract similar documents |
| M. Yu. Dmitryukova, A. A. Golod, M. E. Senina, A. E. Gushchin | ||
| Vol 16, No 1 (2023) | Non-invasive respiratory support in patients with severe community-acquired pneumonia | Abstract similar documents |
| S. V. Korotchenko, D. I. Korabelnikov | ||
| "... forms of COVID-19. At the beginning of COVID-19 pandemic the starting respiratory protocol suggested ..." | ||
| Vol 13, No 4 (2020) | Peptides contained in the composition of Laennec that contribute to the treatment of hyperferritinemia and iron overload disorders | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, V. A. Maksimov, A. G. Chuchalin, V. G. Zgoda, А. N. Gromov, O. V. Tikhonova | ||
| Vol 14, No 4 (2021) | Development of the system of state financing of Compulsory Health Insurance | Abstract similar documents |
| А. V. Larionov, S. V. Russkikh, S. V. Maslennikov | ||
| Vol 16, No 4 (2023) | Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, S. N. Avdeev, I. N. Barykina, V. O. Lutova, E. A. Popova | ||
| "... gained (LYGs) and 1.12 quality-adjusted life years (QALYs) per 1 patient during lifelong therapy ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis | Abstract similar documents |
| A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova | ||
| "... ) with a recalculation into quality-adjusted life-year (QALY). The time horizon of the cost-effectiveness analysis was 2 ..." | ||
| Vol 17, No 3 (2024) | Review of open libraries for pharmacoeconomic analysis in R environment | Abstract similar documents |
| I. A. Lackman, R. I. Sladkov, V. M. Timiryanova | ||
| "... in the R environment was carried out based on the keywords “health economic”, “DALY”, “QALY” in the CRAN ..." | ||
| Vol 15, No 1 (2022) | Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation | Abstract similar documents |
| T. O. Bessonova, F. V. Gorkavenko, D. G. Shchurov, Yu. V. Seryapina, O. R. Chetverikova, V. V. Omelyanovskiy, S. N. Krivolapov, N. M. Neminushchiy, A. A. Kalemberg | ||
| "... and quality-adjusted life years (QALY). Primary prevention model was focused on patients after myocardial ..." | ||
| Vol 15, No 3 (2022) | Funding for coronavirus health worker payments | Abstract similar documents |
| I. Yu. Bocharova, A. Yu. Rymanov | ||
| "... Objective: to conduct an analysis of the channels, the volume of COVID payments to medical workers ..." | ||
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| "... of type 2 DM therapies liraglutide (Victoza®) was considered as the cost-effective strategy with ICER/QALY ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... and extremely severe COPD (FEV1 <50%, CAT ≥10, mMRC ≥2, with severe symptoms). QALY (quality-adjusted life-year ..." | ||
| Vol 15, No 4 (2022) | Pharmacoeconomic analysis of antithrombotic therapy in patients with acute coronary syndrome and patients with atrial fibrillation who underwent percutaneous coronary intervention | Abstract similar documents |
| V. А. Ryagina, К. I. Matrenin, D. G. Shchurov, Т. S. Teptsova | ||
| "... period of the analysis was 5 years. Quality-adjusted life year (QALY) was used as an efficiency criterion ..." | ||
| Vol 6, No 3 (2013) | COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... добавленных лет жизни с качеством 100% (QALY). Из расчета лечения одного пациента, страдающего ХФ ХМЛ, на ..." | ||
| Vol 11, No 3 (2018) | Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review | Abstract similar documents |
| D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin | ||
| "... (QALYs), adverse events, and other clinical outcomes. The search for the relevant information ..." | ||
| Vol 14, No 4 (2021) | Economic burden of chronic viral hepatitis C | Abstract similar documents |
| R. A. Yakhina, I. A. Lakman, D. A. Valishin, R. Kh. Bakhitova | ||
| "... , quality of life adjustment tools (QALY or DALY) were used to estimate the global economic burden. A third ..." | ||
| Vol 9, No 1 (2016) | COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA | Abstract similar documents |
| G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy | ||
| "... + alloSCT vs Ch ± RT per life year (LY) and quality-adjusted life year (QALY) was calculated. In the second ..." | ||
| Vol 14, No 4 (2021) | Peptides of Laennec® preparation that contribute to the elimination of endotheliopathy | Abstract similar documents |
| I. Yu. Torshin, О. А. Gromova, V. G. Zgoda, А. G. Chuchalin, V. А. Maksimov, О. V. Tikhonova | ||
| "... important in the rehabilitation of patients who have recovered from COVID-19. ..." | ||
| Vol 17, No 3 (2024) | Biologically active supplements overview: regulation, market trends, application, and health impact | Abstract similar documents |
| A. M. Stepanova, A. N. Plutnitskiy, E. V. Gameeva | ||
| "... . The public health crisis caused by the COVID-19 pandemic as well as concerns about vaccines in many parts ..." | ||
| Vol 16, No 1 (2023) | Systematic computer analysis of the pharmacology of bioflavonoids in the context of increasing the body's antiviral defenses | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, A. G. Chuchalin | ||
| "... with COVID-19 and other respiratory viral infections were described in detail. Conclusion. Bioflavonoids ..." | ||
| Vol 14, No 2 (2021) | Systematic computer analysis of published literature on nutritional support for vaccination | Abstract similar documents |
| A. G. Chuchalin, I. Yu. Torshin, O. A. Gromova | ||
| "... COVID-19. Additional micronutrient supply contributes to an increase in the effectiveness and safety ..." | ||
| 1 - 44 of 44 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
